Osiris Therapeutics Report issue

For profit Phase 2 Phase 3
Founded: Columbia MD United States (1992)
Status: Acquired by Smith & Nephew (2019)

Organization Overview

First Clinical Trial
2005
NCT00136903
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Osiris Therapeutics | Osiris Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

autologous mesenchymal stem cells (2 trials)

cham (1 trial)

remestemcel-l (2 trials)

Drugs in Phase 2 Trials (1)

hyaluronic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 3)

Foot Ulcer (Phase 3)

Graft vs Host Disease (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4